Icecure Medical Ltd ICCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
-
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
-
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
-
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
-
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
-
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
-
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
-
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
Trading Information
- Previous Close Price
- $3.65
- Day Range
- $3.37–3.72
- 52-Week Range
- $2.12–42.00
- Bid/Ask
- $3.33 / $3.67
- Shares Outstanding
- 3.43M
- Market Cap
- $12.13M
- Volume/Avg
- 99,396 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 66
- Website
- https://www.icecure-medical.com
Valuation
|
Metric
|
ICCM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.16 |
Price/Sales | 2.31 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ICCM
|
|---|---|
Quick Ratio | 1.97 |
Current Ratio | 2.52 |
Interest Coverage | −265.83 |
Quick Ratio
ICCM
Profitability
|
Metric
|
ICCM
|
|---|---|
Return on Assets (Normalized) | −113.16% |
Return on Equity (Normalized) | −202.51% |
Return on Invested Capital (Normalized) | −184.19% |
Return on Assets
ICCM
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|Y&<^?y | LOCK|&?vTX | $164B | |||
| Stryker Corp
SYK
| LOCK|x<f?XQ>% | LOCK|x$z | $126B | |||
| Medtronic PLC
MDT
| LOCK|&&Cl?SL | LOCK|<kWC | $107B | |||
| Boston Scientific Corp
BSX
| LOCK|p>@y&^? | LOCK|$PLY | $67B | |||
| Edwards Lifesciences Corp
EW
| LOCK|#Q%cVGB | LOCK|$#!<J | $53B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|ffQXDl | LOCK|R? | $29B | |||
| DexCom Inc
DXCM
| LOCK|ddX#j#zJ | LOCK|#RSl | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|d#> | LOCK|?$> | $27B | |||
| Steris PLC
STE
| LOCK|#>JV<^! | LOCK|Y^?d! | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|Lv!k@lk | LOCK|p$ | $18B |
United States